Effects of adding 1 mol % of gramicidin-A on the biochemical properties of coexisting liquid-ordered and liquid-disordered (L + L) membrane domains were investigated. Quaternary giant unilamellar vesicles (GUV) of di18:1PC(DOPC)/di18:0PC(DSPC)/cholesterol/gramicidin-A were prepared using our recently developed damp-film method. The phase boundary of L + L coexisting region was determined using video fluorescence microscopy. Through fitting Nile Red fluorescence emission spectra, the thermodynamic tie-lines in the L + L two-phase region were determined. We found that at 1 mol % (i.e., ∼7% of membrane area), gramicidin peptides alter the phase boundary and thermodynamic tie-lines. Gramicidin abolishes the coexisting phases at some lipid compositions but induces phase separation at others. Previous studies of gramicidin emphasize the local perturbation of bilayer thickness adjacent to the protein through the interaction of "hydrophobic mismatch". For the first time, it becomes clear that adding gramicidin produces significant long-range and global effects on the structure of membrane domains: it alters the overall lipid compositions and bilayer thicknesses of coexisting L and L domains. We also found that gramicidin partitions favorably into the L phase. Adding gramicidin decreases cholesterol in the L phase and increases cholesterol in the L phase. Those compositional changes broaden the bilayer thickness difference between L and L domains and facilitate preferential partition of gramicidin into thinner L domains. Our results demonstrate that membrane proteins play significant roles in determining lipid compositions and bilayer thicknesses of biomembrane domains.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.langmuir.6b03688 | DOI Listing |
PLoS One
January 2025
Liaoning Ocean and Fisheries Science Research Institute, Liaoning Academy of Agricultural Sciences, Dalian, PR China.
Objective: This study aimed to evaluate the positive effects on anti-oxidation, anti-inflammation, and microbial composition optimization of diabetic mice using tussah (Antheraea pernyi) silk fibroin peptides (TSFP), providing the theoretical foundation for making the use of silk resources of A. pernyi and incorporating as a supplement into the hypoglycemic foods.
Method: The animal model of diabetes was established successfully.
Int J Syst Evol Microbiol
January 2025
Department of Research and Innovation, MATIS, Reykjavk, Iceland.
A novel bacterium, designated 19SA41, was isolated from the air of the Icelandic volcanic island Surtsey. Cells of strain 19SA41 are Gram-stain-negative, strictly aerobic, non-motile rods and form pale yellow-pigmented colonies. The strain grows at 4-30 °C (optimum, 22 °C), at pH 6-10 (optimum, pH 7.
View Article and Find Full Text PDFUnlabelled: One of the principles of prevention and non-drug treatment of liver diseases, including hepatitis of various etiologies, is the normalization of the diet, including the use of daily diet foods with physiologically active ingredients, in particular betulin, which helps to reduce metabolic and oxidative processes within liver cells. The aim of the work was to evaluate the in vivo effect of triterpene alcohol betulin Roth isolated from the bark of birch Betula pendula Roth. added to fat-containing products (for example, mayonnaise) on the biochemical parameters of blood and the morphological structure of the liver of rats with initiated acute toxic hepatitis.
View Article and Find Full Text PDFPlant Foods Hum Nutr
January 2025
Consejo Nacional de Investigaciones Científicas y Técnicas, Godoy Cruz 2290 (C1425FQB), Buenos Aires, CABA, República Argentina.
Sambucus australis is a wild species with purple fruits like berries. It is native from South America and can be found in Argentina, Uruguay, Paraguay, Bolivia, and Brazil. A comprehensive characterization of S.
View Article and Find Full Text PDFAm J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Oral bempedoic acid (NEXLETOL in the USA; Nilemdo in the EU) and the fixed dose combination (FDC) of bempedoic acid/ezetimibe (NEXLIZET in the USA; Nustendi in the EU) are approved to reduce cardiovascular (CV) risk in statin-intolerant patients who are at high risk for, or have, CV disease. A first-in-class therapy, bempedoic acid inhibits the adenosine triphosphate-citrate lyase enzyme in the cholesterol biosynthesis pathway. In the multinational phase III CLEAR Outcomes trial in statin-intolerant patients, once-daily bempedoic acid 180 mg significantly reduced the risk of the primary endpoint (a four-component major adverse CV event composite of CV death, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization) compared with placebo.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!